Avid Bioservices Inc (CDMO)

[Frustrated]

By Request: For the newbies so they have all the information:

PPHM THE COMPANY THAT STATES IT HAS AN INDEPENDENT BOARD YET 75% OF THE COMPANY WHICH INCLUDES ERIC SCWARTZ, DAVID POHL AND CARLTON JOHNSON ALL SERVED ON THE PENNY STOCK COMPANY PTSC AND ALL HAVE TIES TO EACH OTHER.

PPHM THE COMPANY WHOSE CEO IN MARCH 2014 TALKED ABOUT A PARTNERSHIP COMING TO FRUITION IN UPCOMING YEAR. IT IS NOW JANUARY 10, 2015. CREDIBILITY IS AN ISUUE.

PPHM THE COMPANY WHO PLANNED TO PRESENT HCV DATA AT A MAJOR CONFERENCE IN 2012. NOW JANUARY 10, 2015.

PPHM THE COMPANY WHOSE CEO HOPED TO HAVE A COMMERCIAL PRODUCT BY MID JUNE 2012. NOW JANUARY 10, 2015.

PPHM THE COMPANY WHOSE CEO WANTED A PARTNER BEFORE PHASE III PROTOCOL FOR BAVI AND COTARA. NO PARTER AS OF JANUARY 10, 2015

PPHM THE COMPANY THAT ANNOUNCED IT HAD A SHANGHAI SUBSIDIARY IN 2007. HASN'T BEEN HEARD FROM SINCE.

PPHM THE COMPANY WHOSE TOP EXECUTIVES, ZEISBALL, LYTLE AND SHAN TO NAME A FEW DO NOT PARTICIPATE IN THE COMPANY DISCOUNT STOCK PURCHASE PLAN EVEN THOUGH THEY MAY KNOW HOW VALUABLE THE COMAPNY IS.

PPHM THE COMPANY WHOSE COB CARLTON JOHNSON VOWED TO GET TO THE BOTTOM OF THE BOTCHED TRIAL. NOW JANUARY 10, 2015 WITH NO RESOLUTION.

PPHM THE COMPANY THAT IS A 10 YEAR DOWNTREND WITH STOCK DOWN ROUGHLY 75% OVER THAT TIME AND MORE THAN 50% SINCE REVERSE SPLIT IN 2009.

PPHM THE COMPANY WHOSE CEO STATED IN 2010 THAT THEY WERE LOOKING FOR QUALIFIED CANDIDATES TO ADD TO THE BOARD IN RESPONSE TO CARLTON JOHNSON'S APPOINTMENT AS COB. AS OF JANUARY 10, 2015 NO ADDITIONS TO BOARD.

PPHM THE COMPANY WITH NO EARNINGS AND $260M MARKET CAP WHOSE BOD MEMBERS EARN MORE THE MAJORITY OF MULTI-BILLION DOLLAR, INTERNATIONAL FORTUNE 500 CAMPANIES

PPHM, THE COMPANY THAT ENTERED INTO A $50M PARTNERSHIP DEAL WITH DIOS, A COMPANY THAT DOESN'T EXIST

PPHM THE COMPANY THAT... well... read it for yourself:

TWST: Can you give us a realistic picture as to where you see Peregrine in the year 2005?

Mr. King: I see the company as hopefully having partnered Cotara to move that program forward. By then, I would hope that we could be nearing the completion of the Phase III clinical trial. The timing of that will be dependent on the partner. I view the company as really focusing its efforts on vascular targeting and the Vasopermeation Enhancement Agent programs. I view us as having strong clinical programs in both of those areas.

Biotechnology >> CEO Interview >> July 28, 2003

http://www.twst.com/interview/16148


What year is it now?

Please feel free to add to the list as I am sure they are numerous things left out. ALL IMO.